[Skip to Content]
[Skip to Content Landing]
Views 1,746
Citations 0
Invited Commentary
December 26, 2019

Proton-Based Chemoradiotherapy—What Level of Evidence Is Necessary to Justify Its Widespread Use?

Author Affiliations
  • 1Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut
  • 2Center for Outcomes, Public Policy, and Effectiveness Research, Yale University School of Medicine, New Haven, Connecticut
JAMA Oncol. 2020;6(2):246-247. doi:10.1001/jamaoncol.2019.4875

In this issue of JAMA Oncology, Baumann et al1 present a large single-institution retrospective analysis of proton- vs photon-based radiotherapy specifically for patients receiving concurrent chemotherapy for 11 types of locally advanced cancers. Patients undergoing proton therapy overall had significantly fewer grade 3 toxic effects requiring hospitalization at 90 days, as well as fewer grade 2 toxic effects at 90 days and a smaller decline in performance status during treatment.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×